Treatment Trials

1 Clinical Trials for Various Conditions

TERMINATED

Phase I Study of Milatuzumab for Graft Versus Host Disease

Description

This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.

Conditions

GVHD (Acute or Chronic)Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)Myelodysplastic Syndrome Chronic Myelogenous Leukemia (CML)Multiple Myeloma (MM)Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)